TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04939051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Ultrasonographic Elastography
Description: Undergo liver ultrasound with elastography

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liver Ultrasonographic Elastography
Description: Undergo liver ultrasound with elastography

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary study
Study: NCT03762395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: 6 weeks of treatment with 150 mg/day of orally administered CXA-10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
Study: NCT05905952

Intervention type: DIAGNOSTIC_TEST
Intervention: balance and ROM assessment
Description: assessment of postural stability and ankle range of motion

Intervention type: DIAGNOSTIC_TEST
Intervention: balance and ROM assessment
Description: assessment of postural stability and ankle range of motion
Study: NCT06081660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACP-I Plan
Description: ACP-I Plan consisting of education, counseling, decisional support, and patient navigation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP-I Plan
Description: ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
Study: NCT06267326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridment
Description: resection of dead bone

Intervention type: PROCEDURE
Group type: OTHER
Intervention: debridment
Description: resection of dead bone
Study: NCT04966351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Misalignment
Description: Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Misalignment
Description: Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
Study: NCT06019130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis
Study: NCT05531123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg I.V. Q3W on the day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg I.V. Q3W on the day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified hypofractionation
Description: * Whole bladder 44Gy / 16fractionation (If N1: Whole bladder + Pelvic nodes 44Gy / 16fractionation) (Positive lymph nodes can be dosed to the maximum tolerable dose)~* Tumor boost 11Gy / 4fractionation~* Radiosensitizing chemotherapy: DDP 75-80 mg/m2 weekly Q3W
Study: NCT05234892

Intervention type: DEVICE
Intervention: ALTO endograft implantation
Description: Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
Study: NCT05178147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression bandaging without reference to GraduCheck pressure measurements
Description: To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression bandaging using GraduCheck pressure measurements to monitor compression pressure
Description: To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
Study: NCT05959369

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: y balance test, core endurance and strength test, foot posture ındex
Description: First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
Study: NCT06373406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHB036C
Description: An antibody-drug conjugate therapy
Study: NCT06120881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
Study: NCT05585502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training (minute oscillation stretching)
Description: The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.
Study: NCT05476679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012
Description: 50mg/ml drug formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+Lidacaine injection prior treatment
Description: 5ml lidocaine will be injected 10 minutes before RZL-012 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+Medrol
Description: oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+Celecoxib+Zyrtec
Description: 200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012+facial and neck wrap
Description: Universal Facial Band
Study: NCT05514028

Intervention type: OTHER
Intervention: Salivary samples
Description: For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)

Intervention type: OTHER
Intervention: Salivary samples
Description: For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)

Intervention type: OTHER
Intervention: Salivary samples
Description: For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)
Study: NCT05329428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation 20 µg/day
Description: At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation 40 µg/day
Description: At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Antenatal Care
Description: In early pregnancy (gestational week \<15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
Study: NCT05947344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-8591
Description: Seven dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg,80mg,120mg, 160mg, 200mg, 240mg.Expansion is planned in three dose groups of 120mg, 160mg, and 200mg.
Study: NCT06535451

Intervention type: OTHER
Intervention: Screening
Description: Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
Study: NCT04945174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory exercise combined with patient education and individual follow-up sessions
Description: 6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
Study: NCT06478147

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Nutritional Supplement
Description: Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement + Whey Protein Hydrolysate
Description: Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Hydrolysate + still water
Description: Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
Study: NCT05505669

Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.

Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.

Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.

Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.

Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.

Intervention type: OTHER
Intervention: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Description: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Study: NCT06274190

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bowel e-diary
Description: This bowel diary will be available on the smartphone in the form of an application.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bowel e-diary
Description: This bowel diary will be available on the smartphone in the form of an application.
Study: NCT04058769

Intervention type: DEVICE
Group type: OTHER
Intervention: Premedication Guide
Description: Software with guidelines recommendations for preoperative assessment

Intervention type: DEVICE
Group type: OTHER
Intervention: Premedication Guide
Description: Software with guidelines recommendations for preoperative assessment
Study: NCT05041439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Participants will receive 5 one-on-one sessions with a CHW over 6 months.
Study: NCT05809583

Intervention type: DRUG
Intervention: Ozanimod
Description: Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care
Study: NCT05509634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20013 for injection；dexamethasone
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
Description: fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Study: NCT02763527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking reduction
Description: A brief intervention on smoking reduction plus a smoking reduction leaflet
Study: NCT06189755

Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
Study: NCT06410937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy without drain
Description: thyroidectomy without subcutaneous suction drain
Study: NCT02763527

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation
Description: A brief advice on quitting plus a leaflet on smoking cessation
Study: NCT05641493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HLX208+HLX10
Description: HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
Study: NCT05253625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to a recorded lullaby.
Description: A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to a recorded lullaby.
Description: A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
Study: NCT05817383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry Powder
Description: Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
Study: NCT05746624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keypresses
Description: benign behavioral intervention-- keypresses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keypresses
Description: benign behavioral intervention-- keypresses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keypresses
Description: benign behavioral intervention-- keypresses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keypresses
Description: benign behavioral intervention-- keypresses
Study: NCT06477900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reception
Description: reception of 72 SMS encouraging physical activity and nutritional advice
Study: NCT06261489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
Study: NCT05337280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio OA/US
Description: Imagio optoacoustic/ultrasound